The global lymphoma treatment market size was valued at USD 6.94 billion in 2018 and is projected to reach USD 13.11 billion by 2026, exhibiting a CAGR of 8.3% during the forecast period
Hepatosplenic T-cell lymphoma (HSTCL) is a rare but aggressive form of non-Hodgkin’s lymphoma most common in adolescents and young adults. Only about 200 casesTrusted Source exist in medical literature.
Lymphoma is a group of cancers that develop in a category of white blood cells called lymphocytes. Based on how the cancer cells appear under a microscope, doctors split lymphomas into two main categories: Hodgkin’s and non-Hodgkin’s lymphoma.
Experts expect more than 80,000Trusted Source people in the United States to receive a non-Hodgkin’s lymphoma diagnosis in 2022, compared with about 8,540Trusted Source for Hodgkin’s lymphoma.
Get a Sample Copy of the Report at – https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100262
About 5% to 15%Trusted Source of non-Hodgkin’s lymphomas are peripheral T-cell lymphomas. This type of cancer tends to be aggressive and develops in white blood cells called T cells and natural killer cells.
The development of lymphoma is still not well understood. Most people with HSTCL develop it with no known cause, but about 20%Trusted Source of the time, HSTCL develops in people with immunosuppression. It’s especially prevalent in people with:
- autoimmune disorders
- inflammatory bowel disease (IBD)
- previous blood cancer
- a solid organ transplant
Scientists have identified several gene mutations as risk factors for developing HSTCL.
About 63%Trusted Source of people with HSTCL have a genetic mutation called isochromosome 7q. About 50% of people have an extra copy of chromosome 8 (trisomy 8).
Key players covered in the global Lymphoma Treatment Market research report:
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Bayer AG
- Novartis AG
- Kite Pharma, Inc. / Gilead Sciences, Inc.
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- CELGENE CORPORATION (Bristol Myers Squibb Company)
- Merck & Co., Inc.
- Kyowa Kirin Co., Ltd.
- AbbVie Inc.
- Sanofi
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Comments
Post a Comment